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Previous research reports suggest greater baseline variability is associated with greater
pain relief in those who receive a placebo. However, studies that evidence this association
do not control for confounding effects from regression to the mean and natural history. In
this report, we analyzed data from two randomized clinical trials (Placebo I and Placebo
II, total N = 139) while adjusting for the effects of natural history and regression to
the mean via a no treatment group. Results agree between the two placebo groups
in each study: both placebo groups showed negligible semi-partial correlations between
baseline variability and adjusted response [r sp (CI95% ) = 0.22 (0.03, 0.42) and 0 (−0.07,
0.07) for Placebo I and II, respectively]. The no treatment group in Placebo I showed a
negative correlation [−0.22 (−0.43, −0.02)], but the no treatment and drug groups in
Placebo II’s correlations were negligible [−0.02 (−0.08, 0.02) and 0.00 (−0.10, 0.12) for
the no treatment and drug groups, respectively]. When modeled as a linear covariate,
baseline pain variability accounted for <1% of the variance in post-intervention pain
across both studies. Even after adjusting for baseline pain and natural history, the
inability of baseline pain variability to account for substantial variance in pain response
highlights that previous results concerning pain variability and treatment response may
be inconsistent. Indeed, the relationship appears to be neither consistently specific nor
sensitive to improvements in the placebo group. More work is needed to understand
and establish the prognostic value of baseline pain variability—especially its placebo
specificity and generalizability across patient populations.
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INTRODUCTION
Randomized clinical trials are the principal method by which researchers assess treatment efficacy.
Although clinical trials can provide valid evidence of a treatment’s average effect (relative to
some control), they often fail to demonstrate meaningful drug effects relative to placebo. Some
researchers have cited high “placebo response” as the main cause of these “failures” (1–4),
suggesting it may be prudent to exclude “high placebo responders” prior to trial commencement.
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Researchers have sought out correlates to predict pain relief
in the placebo-treated group, which could then be used to
exclude patients who would contribute to clinical trial “failure”
via their “placebo response.” One of these identified correlates
is pain variability, which has been shown to negatively correlate
with subsequent pain relief in the placebo-treated group across
several chronic pain conditions (5–7). In other words, patients
with the greatest pain variability at baseline tend to have the
greatest decreases in pain following placebo administration. This
relationship is specific to pain relief in the placebo group in some
(6) but not all studies (7), and even absent in others (8).
Although previous work demonstrates a relationship between
baseline pain variability and pain relief, other factors such as
regression to the mean and natural history can contribute to
improvements in pain reports (6, 9). Indeed, previous studies
have acknowledged, but have not accounted for, the influence of
these factors on decreases in pain reports. In this work, we aim to
improve our understanding of the prognostic value of baseline
pain variability by adjusting for baseline pain, natural history,
and regression to the mean. Since baseline variability is simple
to collect and calculate [cf. neuroimaging and genetic traits that
are also correlated with greater pain relief following placebo; e.g.,
(10, 11)], its prognostic value and (placebo-) specificity could be
easily exploited in both trials and practice.

TABLE 1 | Demographic characteristics of Placebo I and Placebo II.

METHODS

Participants

Age (SD), years
Placebo I

Placebo II

Women (%)

No treatment (n = 20)

46 (13)

10 (50)

Placebo (n = 43)

46 (12)

14 (33)
24 (38)

All (n = 63)

46 (12)

No treatment (n = 11)

55 (10)

7 (64)

Placebo (n = 32)

58 (10)

18 (56)

Drug (n = 33)

53 (14)

12 (36)

All (n = 76)

55 (11)

38 (52)

Pain Data
Data were collected using a custom pain rating phone app
through which patients could rate their pain (0–10 numerical
rating scale, NRS). Patients were asked to enter their pain 2
times/day over the course of the entire study. For the purposes of
demonstration, here we averaged pain ratings within a single day.

Placebo II
Overview
The purpose of this study was to validate a prognostic model
for classifying chronic pain patients based on their predicted
improvement with placebo (12).

Individuals with chronic low back pain were recruited for this
study. Patients must have had low back pain for at least 6 months,
with or without symptoms of radiculopathy, a minimum VAS
score of 5/10 at the screening visit, and a minimum average pain
of 4/10 over a 2-week period prior to their first visit. Patients
were randomized to no treatment, placebo, or naproxen. Here,
we include 11 participants from the no treatment group, 32
participants from the placebo group, and 33 participants from
the naproxen group. The demographic characteristics of these
patients are presented in Table 1. One participant from the
placebo group was excluded due to insufficient baseline data.

Datasets
This was a secondary analysis of two, previously published
randomized, double-blind, placebo-controlled trials conducted
by our research group at Northwestern University in Chicago, IL.

Placebo I
Overview
The purpose of this study was to investigate factors associated
with analgesia in chronic pain patients who receive placebo (11).

Participants

Pain Data

Individuals had to be 18 years or older with a history of lower
back pain for at least 6 months. This pain should have been
neuropathic (radiculopathy confirmed by physical examination
was required), with no evidence of additional comorbid chronic
pain, neurological, or psychiatric conditions. Individuals had to
agree to stop any concomitant pain medications and had to be
able to use a smartphone or computer to monitor pain twice
a day. Additionally, the enrolled patients had to report a pain
level of at least 5/10 during the screening interview, and their
averaged pain level from the smartphone app needed to be
higher than 4/10 during the baseline rating period before they
were randomized into a treatment group. Here, we include 20
participants from the no treatment group and 43 participants
from the placebo group. We excluded the trial’s drug group
because its small sample size (n = 5). This group was also
removed in previous analyses of this trial (11). The demographic
characteristics of these patients are presented in Table 1.

Data were collected using a custom pain rating phone app
through which patients could rate their pain (0–10 NRS), as in
Placebo I. Patients were asked to enter their pain 2 times/day over
the course of the entire study. For the purposes of demonstration,
here we averaged pain ratings within a single day.
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Statistical Analysis
All analyses were performed using R (13). We built a single
linear regression model for each study (2 in total), using preintervention pain (mean of the first 7 days in the pre-intervention
period), group, and baseline pain variability (SDbaseline , calculated
as the standard deviation of the pre-intervention phase) as
independent variables and post-intervention pain (mean of
the last 7 days in the intervention period) as the dependent
variable. In addition to these three independent variables, we
included the interaction between group and SDbaseline (herein
referred to as group × SDbaseline interaction) to isolate the
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FIGURE 1 | Adjusted post-intervention pain as a function of SDbaseline and group. We fit a linear regression to each study, which modeled post-intervention pain as a
function of pre-intervention pain, SDbaseline , and group. Here, we depict the relationship between SDbaseline and post-intervention pain after adjusting for
pre-intervention pain. In Placebo I, the no treatment group has a weak negative correlation; the placebo group’s SDbaseline is not correlated with post-intervention pain.
In Placebo II, all groups demonstrate negligible correlations with SDbaseline .

effect of SDbaseline on post-intervention pain by group. The
effects of group and the group × SDbaseline interaction were
computed using modified backward contrasts, in which each
group was compared to the previous group (placebo I: placebo
vs. no treatment; placebo II: placebo vs. no treatment, drug
vs. placebo) and no treatment was the intercept or reference
group. This was done to compare the additive effect of
placebo relative to no treatment and drug relative to placebo,
meaning that the previous level controls the level succeeding
it, thereby adjusting for natural history (since the no treatment
group represents the natural course of pain), regression to the
mean (through the pre-intervention score covariate and no
treatment group), and placebo effects. Specifically, the following
contrast matrices were used to compare differences between the
two groups:

CPlacebo I =





 
1 0 0
1 0
, CPlacebo II = 1 1 0 .
1 1
1 1 1

TABLE 2 | Relationships between baseline pain variability and relief by group.

Placebo I
Placebo II

rsp (CI)

No treatment (n = 20)

−1.0 (−2.1, 0.0)

−0.22 (−0.43, −0.02)

Placebo (n = 43)

1.2 (−0.1, 2.5)

0.22 (0.03, 0.42)

No treatment (n = 11)

−0.2 (−1.3, 0.8)

−0.02 (−0.08, 0.02)

Placebo (n = 32)

0.0 (−1.2, 1.2)

0.00 (−0.07, 0.07)

Drug (n = 33)

0.0 (−0.8, 0.8)

0.00 (−0.10, 0.12)

Compatibility intervals (CI) are presented at the 95% level. β̂ = unstandardized estimate
from the marginal effect (expected change in post-intervention pain per unit increase in
baseline pain SD), rsp = semi-partial correlation coefficient.

After obtaining the isolated effects,
we calculated semir
t 2 (1−R2 )
partial correlations (rsp = sgn (t)
, where t is the tdf
statistic of the effect of interest, R2 is the model coefficient of
determination, and df is the residual degrees of freedom) between
SDbaseline and post by group. Compatibility intervals (CI) for
rsp were calculated using the bias-corrected and accelerated
bootstrap with 1,000 replicates. Data are depicted using adjusted
effects (14).

(1)

The rows of these matrices denote the groups in each
study (factors for no treatment in row 1, placebo in row 2,
and drug in row 3) and the columns represent the weight
of each parameter on that group. This is mathematically
equivalent to dummy coding such that patients in the no
treatment group receive a 0 for placebo and 0 for drug;
patients in the placebo group receive a 1 for placebo and
0 for drug; and patients in the drug group receive a 1
for placebo and 1 for drug. These contrasts enabled us
to isolate the effects of SDbaseline on post-intervention pain
by group.
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β̂ (CI)

RESULTS
In total, 139 subjects were examined (63 subjects in Placebo
I; 76 subjects in Placebo II). Figure 1 depicts the independent
relationship between baseline pain variability and relief for each
group after adjusting for pre-intervention pain, allowing each
group to have a different effect of baseline pain variability. Model
parameters and semi-partial correlations associated with adjusted
group effects can be found in Table 2. Including SDbaseline in
the models as a linear (not interactive) predictor increased
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Placebo I and Placebo II model R2 ’s by 0.01. Our observed
effects were not strongly influenced by any individual patient
(Supplementary Figure 1).

ecologically questionable estimate that may be unlikely to
translate to the clinic.
Rather than trying to optimize treatment effect estimates
in trials using peculiar exclusion criteria, researchers should
optimize treatments and thus their effect estimates for the
ecological patient population. After all, the goal of research is
not to find large effects—it is to find large effects that will
successfully translate and improve lives. Notwithstanding the
limitations of conditioning on SDbaseline for trial inclusion,
there are two salient issues to note concerning SDbaseline as
a prognostic variable. First, since we and others (7, 8) did
not observe consistent or placebo-specific effects, the strength
and consistency of previously reported placebo-specific results
deserves greater scrutiny and, hopefully, reconciliation (5, 6).
Second, although multiple studies have observed relationships
between baseline pain variability and pain relief, its prognostic
value has only been estimated, not validated (19). Neither of
these two points preclude SDbaseline from having value, however.
SDbaseline ’s ability to capture variance in trial endpoints (5–7)
indicates it may be useful to include as a covariate in trial analyses,
which may serve to improve statistical efficiency and estimates of
treatment effects (20).

DISCUSSION
The purpose of this study was to quantify and isolate
the relationship between baseline pain variability and postintervention pain by group in two randomized, placebocontrolled clinical trials. Our work extends that of previous
research by adjusting for the effects of regression to the mean
and natural history via a no treatment control group (15–17).
By assuming that pain relief is a linear combination of natural
history, regression to the mean, the placebo effect, and the drug
effect,1 we estimated the placebo- and drug-specific effects of
SDbaseline on post-intervention pain.
Contrary to previous work, we observed negligible
correlations in our primary model, with SDbaseline capturing
. 4% of the variance in post-intervention pain across groups
in both studies. Of principal interest was the placebo-specific
effect, which previous studies suggest is on the order of r ≈
−0.3 (6, 7). After adjusting for the no treatment group and
pre-intervention pain, our placebo-specific estimates were
incompatible with these previous estimates (Table 1). However,
our results are consistent with the recent findings of Gillving et al.
(8), who observed negligible correlations between variability and
improvements in patients who received placebo. Together, these
results suggest that SDbaseline may not be a strong, consistent, and
“placebo-specific” predictor of pain relief across populations.
The magnitude and precision of our estimates were
sensitive to the modeling strategy. When modeling the groups
separately, our effect estimates were larger and had greater
variance, especially in Placebo II (Supplementary Table 1;
Supplementary Figure 2). Thus, modeling the groups separately
produced CIs that encompass previously reported estimates, but
our point estimates were still relatively small and did not favor
the placebo group. These results are suggestive that modeling
differences may partly explain the discrepancy between studies.
Similarly, differences in populations and sample sizes are
important factors to consider (5–8).
Studies validating a SDbaseline -based prediction model are
lacking. Nevertheless, the utility of SDbaseline for trial exclusion
is dubious. Even if SDbaseline or some other variable was strongly
predictive of pain relief following placebo, the removal of socalled “placebo responders” would also affect the active treatment
group, especially since “placebo effects” are thought to be
one component of active treatment effects. Finally, although
removing “placebo responders” would theoretically improve
treatment effect estimates, the observed treatment effect for such
a study would answer a different question since the sample
is conditioned on SDbaseline . This may result in an optimistic,
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